Treatment of inflammatory myopathy: emerging therapies and therapeutic targets
Authors:
- 11 July 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 11 (11) , 1265-1275
Abstract
(2015). Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Review of Clinical Immunology: Vol. 11, No. 11, pp. 1265-1275.Keywords
This publication has 95 references indexed in Scilit:
- Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case seriesDrug Design, Development and Therapy, 2012
- Abatacept and Sodium Thiosulfate for Treatment of Recalcitrant Juvenile Dermatomyositis Complicated by Ulceration and CalcinosisThe Journal of Pediatrics, 2012
- Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprineArthritis Research & Therapy, 2012
- A randomized, pilot trial of etanercept in dermatomyositisAnnals of Neurology, 2011
- Rituximab therapy for myopathy associated with anti–signal recognition particle antibodies: A case seriesArthritis Care & Research, 2010
- Tumor Necrosis Factor Inhibitor–Associated DermatomyositisArchives of Dermatology, 2010
- Mycophenolate mofetil for interstitial lung disease in dermatomyositisArthritis Care & Research, 2010
- Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositisArthritis & Rheumatism, 2007
- Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomesArthritis Research & Therapy, 2007
- Rituximab in the treatment of antisynthetase syndromeAnnals of the Rheumatic Diseases, 2006